Vancouver, BC, December 5, 2024 – SOLVE FSHD, a venture philanthropy organization dedicated to catalyzing innovation and overcoming barriers to accelerate new therapies for facioscapulohumeral muscular dystrophy (FSHD), is calling on innovators worldwide to compete for the USD$10 million FSHD Bonus Prize, part of the XPRIZE Healthspan Competition launched on November 29, 2023. As part of …
SOLVE FSHD AnnouncesNew Collaborative Research Grants to Accelerate Novel Potential Therapeutics for Facioscapulohumeral Muscular Dystrophy (FSHD) VANCOUVER, B.C., July 11, 2023 – SOLVE FSHD, a venture philanthropy organization catalyzing innovation and removing barriers to accelerate new therapies for FSHD, announced today that it has awarded grants totalling USD $1.4M to four new collaborative research projects that address critical …
SOLVE FSHD invests in Epic Bio for the development of a novel treatment for Facioscapulohumeral Muscular Dystrophy Investment will further accelerate the development of EPI-321 VANCOUVER, B.C., April 18, 2023 – SOLVE FSHD, a venture-philanthropic organization catalyzing the pace of innovation to accelerate a cure for FSHD, announced today an investment in Epic Bio, a biotechnology …
– EPI-321 is the first investigational therapy designed to silence DUX4 expression via epigenetic modulation – FDA has granted Fast Track, Rare Pediatric Disease, and Orphan Drug Designation for EPI-321 in FSHD SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Epicrispr Biotechnologies, a clinical-stage company pioneering gene-modulating therapies, today announced that the first patient has been dosed in its …
Cambridge, Mass., May 12, 2025 – Epicrispr Biotechnologies, a biotechnology company focused on developing curative therapies, today announced it has been named a Finalist Team in XPRIZE Healthspan FSHD Bonus Prize, earning a $250,000 Milestone Award for its work addressing facioscapulohumeral muscular dystrophy (FSHD), one of the most prevalent forms of muscular dystrophy globally. Epicrispr was one of eight global …
Columbus, Ohio, May 12, 2025 – Armatus Bio, a late-preclinical stage biotech innovator developing vectorized RNAi medicines in neuromuscular disorders, today announced its recognition as one of eight finalists in the XPRIZE Healthspan FSHD Bonus Prize, led by XPRIZE, the world’s leader in designing and operating large-scale incentive competitions to solve humanity’s grand challenges. SOLVE …